NAYA Biosciences And ONK Therapeutics Announce Research Partnership To Advance Combination Therapy Of FLEX-NK Bispecific Antibodies And Optimally Engineered Off-The-Shelf Natural Killer Cell Therapies
Portfolio Pulse from Benzinga Newsdesk
NAYA Biosciences and ONK Therapeutics have announced a research partnership to evaluate a combination therapy for cancer treatment, involving NAYA's FLEX-NK bispecific antibodies and ONK's engineered natural killer (NK) cell therapies. The partnership will initially focus on preclinical cancer models with the potential to expand into joint clinical development. NAYA is expected to complete its merger with INVO Bioscience (NASDAQ: INVO) in Q1 2024. The collaboration aims to improve treatment options and long-term survival for patients with hepatocellular carcinoma (HCC).
December 06, 2023 | 2:05 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
INVO Bioscience is expected to merge with NAYA Biosciences in Q1 2024, which could expand its life science portfolio to include treatments in fertility, oncology, and regenerative medicine.
The merger between INVO Bioscience and NAYA Biosciences is likely to have a positive short-term impact on INVO's stock price as it expands the company's portfolio and potential market opportunities in the life sciences sector, particularly in oncology and fertility treatments. The announcement of the research partnership with ONK Therapeutics further emphasizes the strategic growth and development in these areas, which could be viewed favorably by investors.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 80